Call Scheduled for Wednesday, February 26, 2025, at 4:30 p.m. ET/1:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 ...

在充满挑战的市场环境下，Alector Inc (ALEC)股价触及新的52周低点，跌至1.59美元。这一显著下跌反映了该生物科技公司的整体趋势，过去一年股价已下跌了75.15%。根据 InvestingPro ...

北京时间2025年01月31日02时20分，Alector, Inc.（ALEC.us）股票出现异动，股价急速拉升5.18%。截至发稿，该股报1.73美元/股，成交量 ...

The U.S. stock market has been showing resilience, with the S&P 500 recently reaching an all-time high and major indices nearing record levels. In this climate, penny stocks—though often ...

北京时间2025年01月29日02时36分，Alector, Inc.（ALEC.us）股票出现异动，股价大幅下跌5.17%。截至发稿，该股报1.65美元/股，成交量 ...

In a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a 52-week low, sinking to $1.59. With a market capitalization of $158.65 million, InvestingPro analysis suggests the ...

11月26日｜美国生物制药公司Alector(ALEC.US)盘前跌超33.5%，报2.63美元。消息面上，Alector表示，该公司的实验性药物在一项中期试验中没有达到减缓阿尔 ...

Alector, Inc., a late-stage clinical biotechnology company, is advancing its preclinical and research pipeline focused on genetically-validated therapies for neurodegenerative diseases.

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically ...

Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have received a consensus rating of “Hold” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports.

As of September 30, 2024, Alector had $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide ...

In November, Alector (NASDAQ:ALEC) reported that a Phase 2 study of the TREM2 agonist drug AL002 failed to meet its primary endpoint in the treatment of early Alzheimer's disease. More on AbbVie ...